It’s Not Your Heart Rate — It’s Your Heart’s Workload
Arginine and citrulline supplementation does not reliably lower heart rate in healthy people. But in those with heart disease, the evidence for reduced cardiac workload and improved heart function is genuinely compelling.
in Heart Failure (Balderas-Munoz 2012)
for LVEF in HF (Salmani 2021)
in Severe HF (Hambrecht 2000)
with Arginine + Exercise
If you searched for arginine or citrulline and heart rate, you may have expected a straightforward story about lower beats per minute. The reality is more interesting — and more useful. These amino acids do not reliably change heart rate in healthy people. What they do, in the right population, is reduce the load the heart has to work against.
The Gap Between Heart Rate and Heart Work
Heart rate is easy to measure, which is why people focus on it. But the work a heart actually performs is determined by more than its rhythm — it depends heavily on the resistance the heart must push blood against. This resistance, called afterload, is set primarily by the stiffness and tone of the peripheral vessels. When arteries are constricted or rigid, the heart must generate greater pressure to eject each stroke volume. Over time, that sustained mechanical burden drives ventricular remodeling, reduced ejection fraction, and progressive cardiac dysfunction.
In heart failure, this cycle is especially damaging. Impaired nitric oxide (NO) synthesis — a hallmark of endothelial dysfunction in HF — contributes directly to peripheral vasoconstriction. Without adequate NO-mediated vasodilation, vessels fail to relax appropriately, afterload rises, and a heart that is already struggling to pump effectively must work even harder against stiffer peripheral resistance. Restoring the NO pathway is therefore not just a vascular intervention; it is a way of directly reducing the mechanical burden on the heart.
This is where arginine and citrulline become relevant — not as heart-rate hackers, but as upstream supports to the vascular pathway that sets how hard the heart has to work.
Arginine and Citrulline: The NO Pathway’s Raw Materials
L-arginine is the sole substrate for endothelial nitric oxide synthase (eNOS), the enzyme that produces the NO keeping blood vessels relaxed. When arginine availability is adequate and the endothelium is healthy, eNOS produces a steady tonic release of NO that maintains vessel dilation, suppresses arterial stiffness, and keeps peripheral resistance in check. L-citrulline is arginine’s metabolic partner: a non-essential amino acid that bypasses the liver’s first-pass metabolism and is converted back to arginine in the kidneys, producing a more sustained elevation in plasma arginine than oral arginine itself achieves.
In people with heart failure or established endothelial dysfunction, the NO pathway is compromised. eNOS is less active, competing inhibitors (particularly ADMA, asymmetric dimethylarginine) are elevated, and oxidative stress degrades what little NO is produced. Supplementing with arginine or citrulline in this context is not adding a stimulant to the system — it is trying to restore a substrate supply that has become inadequate for normal vascular function. That distinction matters for interpreting the evidence.
How Arginine and Citrulline Affect the Cardiovascular System: Four Pathways
Afterload Reduction via Peripheral Vasodilation
NO produced by eNOS diffuses to adjacent vascular smooth muscle, activating soluble guanylate cyclase and increasing cyclic GMP, which triggers muscle relaxation and vasodilation. Wider, more compliant peripheral vessels lower systemic vascular resistance — reducing the pressure the heart must generate to eject blood. The heart pumps the same volume with less mechanical effort.
NO Restores Endothelial Function in Heart Failure
In severe chronic heart failure, endothelium-dependent vasodilation (the vessels’ ability to dilate in response to NO signals) is significantly impaired. Hambrecht et al. (2000) demonstrated in an RCT of 40 NYHA IIIb patients that L-arginine 8 g/day for 4 weeks independently restored this response to acetylcholine — without affecting endothelium-independent dilation — confirming the mechanism is specifically NOS-mediated, not a general vascular effect.
Citrulline Sustains Arginine for eNOS
Oral L-arginine has approximately 20% systemic bioavailability due to hepatic first-pass extraction by arginase. L-citrulline bypasses this degradation entirely, being converted to arginine in the kidneys and entering the circulation as fresh substrate. Schwedhelm et al. (2008, n=20) showed citrulline dose-dependently raised plasma arginine AUC and Cmax more effectively than equivalent oral arginine, improving the arginine-to-ADMA ratio — a marker of NO synthetic capacity.
Exercise and Arginine: Additive in Heart Failure
Hambrecht et al. (2000) also found that arginine supplementation and exercise training had additive effects on endothelial function in severe HF patients when combined — each modality independently improving vasodilation to similar degrees, with the combined group achieving the largest response. This matters practically: the evidence suggests supplementation does not replace exercise but amplifies it when the vascular substrate is restored.
What the Clinical Research Shows
The heart rate story in healthy, active populations is clearly negative. Porto et al. (2025) ran a well-powered triple-blind crossover RCT in 37 healthy active males (18–30 years) and found acute L-arginine (3 g) produced no significant differences versus placebo for any HRV parameter, heart rate recovery, or hemodynamic outcome after exercise. This is not a weak null — it is a properly powered study in the target population, with a clear result. In healthy people with normal vascular tone, there is no excess afterload to reduce, and therefore no mechanism by which arginine would lower heart rate.
The cardiac function story in people with heart disease is a different matter. Three RCTs in heart failure populations consistently report improvements in left ventricular ejection fraction (LVEF), functional class, and endothelial function — with each study using a distinct amino acid, dose, and duration.
In a 4-arm RCT of 40 patients with severe chronic heart failure (NYHA class IIIb), Hambrecht et al. randomized participants to L-arginine 8 g/day, exercise training alone, combined arginine and exercise, or control for 4 weeks. Both arginine and exercise independently restored endothelium-dependent vasodilation — the vessels’ ability to dilate in response to NO signals — to comparable degrees. When combined, the effects were additive.
This study is significant for two reasons: it established that NO substrate supplementation can restore endothelial function even in severe, late-stage HF, and it demonstrated that arginine works through a genuinely different pathway than exercise, meaning the two interventions are complementary rather than redundant. The confirmation that endothelium-independent vasodilation was unaffected rules out non-specific vascular effects.
RCT, n=35 systolic HF
L-citrulline 3 g/day, 4 months
RCT, n=50 ischemic HF
L-arginine 3 g/day, 10 weeks
RCT, n=40 severe HF (NYHA IIIb)
L-arginine 8 g/day, 4 weeks
RCT, n=30 overweight men
L-arginine 6 g, acute, before HIIE
Triple-blind crossover RCT, n=37
Healthy active males, acute 3 g arginine
What This Means for Active People Managing Cardiac Health
Heart failure affects an estimated 64 million people globally, and its prevalence is rising as populations age. A growing segment of the people reading this blog are not elite athletes in perfect cardiovascular health — they are active adults managing early cardiac disease, returning to exercise after a cardiac event, or supporting a family member through heart failure rehabilitation. For this audience, the distinction between “does not lower heart rate” and “reduces the workload on the heart” is not a technicality — it is clinically meaningful.
The mechanism is not mysterious. When peripheral vessels cannot dilate properly because NO synthesis is impaired, the heart compensates by generating higher ejection pressures. Left ventricular ejection fraction — the percentage of blood pumped out with each beat — is therefore partly a function of vascular resistance. Reducing that resistance is a legitimate, non-pharmacological way to support ejection fraction, and the three HF trials reviewed here are consistent on this point. Critically, LVEF improvement in Salmani 2021 came with just 3 g/day of arginine over 10 weeks — a dose well within the established safety margin.
For purely healthy active adults training for performance, the honest message is different: arginine and citrulline do not appear to change heart rate, HRV, or cardiac output in a population where the NO pathway is already functioning normally. The benefit of these amino acids for that population lies in different domains — modest muscular endurance improvements, blood pressure support at higher doses, and post-exercise recovery. The cardiac function evidence belongs in a conversation about vascular health, not sports performance hacks.
What Studies Used: The Evidence-Based Protocol
| Parameter | What Studies Used |
|---|---|
| Dose (HF context) | L-arginine: 3 g/day (Salmani 2021) to 8 g/day (Hambrecht 2000); L-citrulline: 3 g/day (Balderas-Munoz 2012). Both used as single daily doses in the HF trials. |
| Dose (healthy/active) | Acute: 3–6 g arginine pre-exercise (Porto 2025, Daraei 2021). No heart rate or HRV benefit observed in healthy populations at these doses. |
| Form | Free-form L-arginine (HCl or free base) in HF trials. L-citrulline (not citrulline malate) in Balderas-Munoz 2012. L-citrulline provides superior plasma arginine elevation due to avoided hepatic first-pass extraction. |
| Duration | 4 weeks (Hambrecht 2000) to 4 months (Balderas-Munoz 2012) in HF studies. LVEF improvements seen from 10 weeks (Salmani 2021). Cardiac benefits require weeks to months of consistent use. |
| Combine with | Exercise training (additive effects confirmed in Hambrecht 2000 and Kang 2022). Standard HF pharmacotherapy continued in all trials — arginine/citrulline were adjunctive, not replacements. |
| Who benefits most | Heart failure patients and those with established endothelial dysfunction. Healthy young active adults do not show cardiac benefit. Evidence is not generalizable from HF populations to general athletic use for cardiac outcomes. |
| Safety | McNeal et al. (2018, n=101): NOAEL at least 30 g/day over 90 days. No adverse effects reported in the HF trials at 3–8 g/day. GI discomfort possible at single doses above 9 g — mitigated by divided dosing. Individuals with hepatic or renal disease should consult a clinician. |
What the Research Doesn’t Yet Tell Us
The HF evidence is promising but preliminary. All three cardiac trials used small samples (n=35–50), all were single-centre, and crucially, Balderas-Munoz et al. (2012) was open-label — participants and investigators both knew who received citrulline, and there was no placebo group. This introduces the possibility that expectation effects and differential attention influenced the large effect sizes reported. The Salmani 2021 and Hambrecht 2000 studies used placebo comparators and are therefore more methodologically robust, but even these are insufficient for clinical guideline adoption on their own. No study in this space has measured hard cardiovascular endpoints — mortality, hospitalization rates, or major adverse cardiac events. The LVEF and FMD improvements are surrogate markers; their translation to meaningful clinical outcomes in HF management requires larger confirmatory trials.
Additionally, the trials used HF populations with established NO pathway dysfunction — a condition that fundamentally differs from the vascular profile of healthy athletes. Extrapolating the HF cardiac function findings to otherwise healthy active adults is not supported by the evidence. For healthy individuals, the Porto et al. (2025) null finding on HRV and hemodynamics stands as a well-controlled data point. Research has not yet examined whether long-term arginine or citrulline supplementation might produce preventive vascular benefits in athletes at cardiac risk, or in the growing population of “fit but hypertensive” adults. These are genuinely open questions.
Explore the Full Research
- 📄 Clinical Evidence One-Pager (PDF) — concise summary for clinicians and coaches
- 📋 Full Research Paper (PDF) — complete literature synthesis with evidence tables
- 🔗 Full Reference List — all cited sources in Vancouver format
Read the Complete Cardiac Evidence Summary
Our research paper covers the full cardiovascular, ergogenic, and mechanistic evidence base for arginine and citrulline — including blood pressure, endothelial function, and heart failure data from 42 studies.
Download the Full Research PaperKey References
- Hambrecht R, Hilbrich L, Erbs S, et al. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol. 2000;35(3):706–713. PMID: 10716474.
- Salmani R, Farshidi H, Mousavi A, et al. Effects of L-arginine supplementation on left ventricular ejection fraction and quality of life in patients with ischemic heart failure. J Cardiovasc Thorac Res. 2021;13(1):58–63. PMID: 33610421.
- Balderas-Munoz K, Castillo-Martinez L, Orea-Tejeda A, et al. Improvement of ventricular function in systolic heart failure patients with oral L-citrulline supplementation. Cardiol J. 2012;19(6):612–617. PMID: 23224924.
- Porto AA, Gonzaga LA, Benjamim CJR, et al. Acute L-arginine supplementation does not affect heart rate variability and hemodynamic responses after submaximal exercise. Nutrients. 2025;17(10):1726. PMID: 40389021.
- Daraei A, Garelnabi M, Alinejad HA, et al. L-arginine supplementation reduces exercise heart rate in overweight men during high-intensity interval exercise. J Nutr Metab. 2021;2021:8844956. PMID: 33260139.
- Schwedhelm E, Maas R, Freese R, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol. 2008;65(1):51–59. PMID: 17381548.
- McNeal CJ, Meininger CJ, Reddy D, Wilborn CD, Wu G. Safety and effectiveness of arginine in adults. J Nutr. 2016;146(12):2587S–2593S. PMID: 27934655.